Hussain_2023_Pharmaceuticals.(Basel)_16_

Reference

Title : Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer's Disease - Hussain_2023_Pharmaceuticals.(Basel)_16_
Author(s) : Hussain R , Khan S , Ullah H , Ali F , Khan Y , Sardar A , Iqbal R , Ataya FS , El-Sabbagh NM , Batiha GE
Ref : Pharmaceuticals (Basel) , 16 : , 2023
Abstract :

A series of benzimidazole-based Schiff base derivatives (1-18) were synthesized and structurally elucidated through (1)H NMR, (13)C NMR and HREI-MS analysis. Subsequently, these synthetic derivatives were subjected to evaluation for their inhibitory capabilities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). All these derivatives showed significant inhibition against AChE with an IC(50) value in the range of 123.9 +/- 10.20 to 342.60 +/- 10.60 microM and BuChE in the range of 131.30 +/- 9.70 to 375.80 +/- 12.80 microM in comparison with standard Donepezil, which has IC(50) values of 243.76 +/- 5.70 microM (AChE) and 276.60 +/- 6.50 microM (BuChE), respectively. Compounds 3, 5 and 9 exhibited potent inhibition against both AChE and BuChE. Molecular docking studies were used to validate and establish the structure-activity relationship of the synthesized derivatives.

PubMedSearch : Hussain_2023_Pharmaceuticals.(Basel)_16_
PubMedID: 37765088

Related information

Citations formats

Hussain R, Khan S, Ullah H, Ali F, Khan Y, Sardar A, Iqbal R, Ataya FS, El-Sabbagh NM, Batiha GE (2023)
Benzimidazole-Based Schiff Base Hybrid Scaffolds: A Promising Approach to Develop Multi-Target Drugs for Alzheimer's Disease
Pharmaceuticals (Basel) 16 :

Hussain R, Khan S, Ullah H, Ali F, Khan Y, Sardar A, Iqbal R, Ataya FS, El-Sabbagh NM, Batiha GE (2023)
Pharmaceuticals (Basel) 16 :